FREDERICK, Md., Oct. 2, 2019 /PRNewswire/ — An exploratory study, conducted by NetNoggin®, revealed that among those impacted by Alzheimer’s, hope of finding a cure is deflating due to recent Alzheimer’s clinical trial failures in the past few years:
In fact, the last successful Alzheimer’s drug approval was in 2014 for NAMZARIC. Manufacturers acknowledge current drugs for Alzheimer’s only treat symptoms as the disease continues to progress.
In response to news regarding failed clinical trials, caregivers are posting responses claiming this news makes them “depressed’ and “pessimistic”. Yet, researchers and foundations remain hopeful despite the failures. For example, George Vradenburg, the head of USAgainstAlzheimers, posted on Twitter, “Let’s keep failing … until we succeed … [help] us all to remain hopeful in the fight against #Alz.”
Results from NetNoggin‘s analysis also show growing concern that the amyloid hypothesis may be the wrong target and other mechanisms should be considered. The community suggests the following next steps:
Visit https://netnoggin.net/exploratory-analysis to request the full exploratory analysis.
About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® utilizes netnography to analyze and provide context to Big Data. By leveraging 30+ years of experience, their proprietary process derives strategic consulting insights from Big Data to inform Foundational Marketing Tools (FMTs), strategies, and tactics. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops.
NetNoggin® Media Relations
If you would like more information on this topic, please contact Megan Newcomer.
E-mail: megan.newcomer@netnoggin.net
View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-releases-exploratory-analysis-alzheimers-recent-drug-failures-300930053.html
SOURCE NetNoggin
SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (“MNDR” or “the Company”), a…
Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst…
SAN FRANCISCO, April 12, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS)…
Gross Margin Improved 300 basis points to 31% Year-Over-Year Adjusted EBITDA Grew 30% Year-Over-Year EPS…
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link…
This conclusion is the result of almost 10 years of research carried out by the…